Clinical Trial Update: Pilot Study of 89-Zr Panitumumab in Pancreas Cancer [Phase 1]

View source ↗

Summary

A Phase 1 pilot study of Zirconium-89 labeled Panitumumab for pancreatic cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Panitumumab (panitumumab)

Snippet

Sponsor: Stanford University | Conditions: Pancreas Cancer | Phase 1 | Status: WITHDRAWN